SCHEMBL30795283

SCHEMBL30795283

CCOC(=O)Nc1ccc(CNc2cccc(Cl)c2)cc1N

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ2 O43526 6/20 0.65
KCNQ3 O43525 5/20 0.65
KCNQ4 P56696 2/20 0.65
KCNQ5 Q9NR82 2/20 0.65
MAPK1 P28482 3/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
HSD17B10 Q99714 2/20 0.46
ABCB11 O95342 1/20 0.46
ESR1 P03372 1/20 0.46
CYP3A4 P08684 1/20 0.46
HTR1A P08908 1/20 0.46
ADRA2A P08913 1/20 0.46
ADORA3 P0DMS8 1/20 0.46
CYP2D6 P10635 1/20 0.46
ALOX15 P16050 1/20 0.46
NFKB1 P19838 1/20 0.46
TBXA2R P21731 1/20 0.46
CASP1 P29466 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3101258 1.00 KCNQ2 (0.65) KCNQ2KCNQ3KCNQ4KCNQ5MAPK1
SCHEMBL30795095 0.90 KCNQ2 (0.65) KCNQ2KCNQ3KCNQ4KCNQ5MAPK1
SCHEMBL3095370 0.90 KCNQ2 (0.65) KCNQ2KCNQ3KCNQ4KCNQ5MAPK1
SCHEMBL30794719 0.90 KCNQ2 (0.69) KCNQ2KCNQ3KCNQ4KCNQ5MAPK1
SCHEMBL3106790 0.90 KCNQ2 (0.69) KCNQ2KCNQ3KCNQ4KCNQ5MAPK1
SCHEMBL3090804 0.88 KCNQ2 (0.69) KCNQ2KCNQ3KCNQ4KCNQ5MAPK1
SCHEMBL30795239 0.88 KCNQ2 (0.69) KCNQ2KCNQ3KCNQ4KCNQ5MAPK1
SCHEMBL3113156 0.88 KCNQ2 (0.68) KCNQ2KCNQ3KCNQ4KCNQ5MAPK1
SCHEMBL30795962 0.87 KCNQ2 (0.74) KCNQ2KCNQ3KCNQ4KCNQ5MAPK1
SCHEMBL3106791 0.87 KCNQ2 (0.74) KCNQ2KCNQ3KCNQ4KCNQ5MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 EP disclosed
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 EP disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 WO disclosed